Silencing of miR‑19a‑3p enhances osteosarcoma cells chemosensitivity by elevating the expression of tumor suppressor PTEN

Zhang,Bo; Liu,Yuan; Zhang,Jiangnan

doi:10.3892/ol.2018.9592

Silencing of miR‑19a‑3p enhances osteosarcoma cells chemosensitivity by elevating the expression of tumor suppressor PTEN

Authors:
- Bo Zhang
- Yuan Liu
- Jiangnan Zhang
View Affiliations

Affiliations: Department of Orthopaedics, The First People's Hospital of Wenling, Wenling, Zhejiang 317500, P.R. China, Department of Medical Examination, Center for Disease Control and Prevention of Wenling, Wenling, Zhejiang 317500, P.R. China
Published online on: October 17, 2018 https://doi.org/10.3892/ol.2018.9592
Pages: 414-421

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs/miRs) are small non‑coding RNAs, which serve important roles in tumor progression. The present study analyzed the role of miR‑19a‑3p in the chemosensitivity of osteosarcoma (OS) cells. Overexpression of miR‑19a‑3p was observed in OS cells and a cisplatin‑resistant MG63 cell line was subsequently constructed. It was observed that miR‑19a‑3p inhibitor transfection suppressed cell proliferation and decreased the expression of Ki67 and PCNA compared with the cisplatin treatment group. miR‑19a‑3p inhibitor transfection also promoted apoptotic rate, increased the expression of Bcl‑2 associated X, apoptosis regulator (Bax) and markedly decreased the expression of Bcl‑2 compared with the cisplatin treatment group. These results elucidated that silencing of miR‑19a‑3p enhanced chemosensitivity of OS cells to Cisplatin, through suppressing cell proliferation and promoting cell apoptosis during treatment with Cisplatin. Bioinformatics study and luciferase reporter assays indicated that PTEN was a target of miR‑19a‑3p, and western blotting demonstrated that PTEN expression was negatively regulated by miR‑19a‑3p in OS cells. In addition, overexpression of PTEN decreased cell proliferation, but increased apoptotic rate compared with the cisplatin treatment group. It was observed that inhibition of PTEN by BpV(HOpic) upregulated cell proliferation and downregulated apoptotic rate compared with the Cisplatin‑treated miR‑19a‑3p inhibitor group, indicating that inhibition of PTEN expression counteracted the effect of the miR‑19a‑3p inhibitor on the regulation of chemosensitivity in OS cells. Taken together, overexpression of miR‑19a‑3p was observed in OS cell lines and that downregulation of miR‑19a‑3p enhanced the chemosensitivity of OS cells to Cisplatin, by elevating the expression of the tumor suppressor, PTEN.

View Figures

View References

1	Arndt CA, Rose PS, Folpe AL and Laack NN: Common musculoskeletal tumors of childhood and adolescence. Mayo Clin Proc. 87:475–487. 2012. View Article : Google Scholar : PubMed/NCBI
2	Ta HT, Dass CR, Choong PF and Dunstan DE: Osteosarcoma treatment: State of the art. Cancer Metastasis Rev. 28:247–263. 2009. View Article : Google Scholar : PubMed/NCBI
3	Kempf-Bielack B, Bielack SS, Jurgens H, Branscheid D, Berdel WE, Exner GU, Göbel U, Helmke K, Jundt G, Kabisch H, et al: Osteosarcoma relapse after combined modality therapy: An analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol. 23:559–568. 2005. View Article : Google Scholar : PubMed/NCBI
4	Thompson LD: Osteosarcoma. Ear, Nose Throat J. 92:288–290. 2013.
5	Chang Z, Huo L, Li K, Wu Y and Hu Z: Blocked autophagy by miR-101 enhances osteosarcoma cell chemosensitivity in vitro. ScientificWorldJournal. 2014:e7947562014. View Article : Google Scholar
6	Zhou Y, Huang Z, Wu S, Zang X, Liu M and Shi J: miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST. J Exp Clin Cancer Res. 33:122014. View Article : Google Scholar : PubMed/NCBI
7	Wang Y and Lee CG: MicroRNA and cancer-focus on apoptosis. J Cell Mol Med. 13:12–23. 2009. View Article : Google Scholar : PubMed/NCBI
8	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
9	Iorio MV and Croce CM: MicroRNAs in cancer: Small molecules with a huge impact. J Clin Oncol. 27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
10	Lu C, Xie Z and Peng Q: MiRNA-107 enhances chemosensitivity to paclitaxel by targeting antiapoptotic factor Bcl-w in non small cell lung cancer. Am J Cancer Res. 7:1863–1873. 2017.PubMed/NCBI
11	Zhang J, Qiu W, Xu S, Yu Q, Liu C, Wang Y, Lu A, Zhang J and Lu X: ¹MicroRNA-625 inhibits the proliferation and increases the chemosensitivity of glioma by directly targeting AKT2. Am J Cancer Res. 7:1835–1849. 2017.PubMed/NCBI
12	Li Y, Luo T, Wang L, Wu J and Guo S: MicroRNA-19a-3p enhances the proliferation and insulin secretion, while it inhibits the apoptosis of pancreatic β cells via the inhibition of SOCS3. Int J Mol Med. 38:1515–1524. 2016. View Article : Google Scholar : PubMed/NCBI
13	Soria JC, Lee HY, Lee JI, Wang L, Issa JP, Kemp BL, Liu DD, Kurie JM, Mao L and Khuri FR: Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res. 8:1178–1184. 2002.PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Shen J, Niu W and Zhang H, Jun M and Zhang H: Downregulation of MicroRNA-147 Inhibits Cell Proliferation and Increases the Chemosensitivity of Gastric Cancer Cells to 5-Fluorouracil by Directly Targeting PTEN. Oncol Res. doi: 10.3727/096504017X15061902533715. 2017.
16	Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, et al: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 20:776–790. 2002. View Article : Google Scholar : PubMed/NCBI
17	Dasari S and Tchounwou PB: Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol. 740:364–378. 2014. View Article : Google Scholar : PubMed/NCBI
18	Lei W, Yan C, Ya J, Yong D, Yujun B and Kai L: MiR-199a-3p affects the multi-chemoresistance of osteosarcoma through targeting AK4. BMC cancer. 18:6312018. View Article : Google Scholar : PubMed/NCBI
19	Xie B, Li Y, Zhao R, Xu Y, Wu Y, Wang J, Xia D, Han W and Chen D: Identification of key genes and miRNAs in osteosarcoma patients with chemoresistance by bioinformatics analysis. Biomed Res Int. 2018:47610642018. View Article : Google Scholar : PubMed/NCBI
20	Wang SN, Luo S, Liu C, Piao Z, Gou W, Wang Y, Guan W, Li Q, Zou H, Yang ZZ, et al: miR-491 inhibits osteosarcoma lung metastasis and chemoresistance by targeting alphaB-crystallin. Mol Ther. 25:2140–2149. 2017. View Article : Google Scholar : PubMed/NCBI
21	Rajabpour A, Afgar A, Mahmoodzadeh H, Radfar JE, Rajaei F and Teimoori-Toolabi L: MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells. Cancer Chemother Pharmacol. 80:765–775. 2017. View Article : Google Scholar : PubMed/NCBI
22	Zou M, Wang F, Gao R, Wu J, Ou Y, Chen X, Wang T, Zhou X, Zhu W, Li P, et al: Autophagy inhibition of hsa-miR-19a-3p/19b-3p by targeting TGF-β R II during TGF-β1-induced fibrogenesis in human cardiac fibroblasts. Sci Rep. 6:247472016. View Article : Google Scholar : PubMed/NCBI
23	Zhu M, Huang Z, Zhu D, Zhou X, Shan X, Qi LW, Wu L, Cheng W, Zhu J, Zhang L, et al: A panel of microRNA signature in serum for colorectal cancer diagnosis. Oncotarget. 8:17081–17091. 2017.PubMed/NCBI
24	Lotan TL, Heumann A, Rico SD, Hicks J, Lecksell K, Koop C, Sauter G, Schlomm T and Simon R: PTEN loss detection in prostate cancer: Comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort. Oncotarget. 8:65566–65576. 2017. View Article : Google Scholar : PubMed/NCBI
25	Ma J, Guo X, Zhang J, Wu D, Hu X, Li J, Lan Q, Liu Y and Dong W: PTEN gene induces cell invasion and migration via regulating AKT/GSK-3β/β-Catenin signaling pathway in human gastric cancer. Dig Dis Sci. 62:3415–3425. 2017. View Article : Google Scholar : PubMed/NCBI
26	Liu F, Zhao X, Qian Y, Zhang J, Zhang Y and Yin R: MiR-206 inhibits Head and neck squamous cell carcinoma cell progression by targeting HDAC6 via PTEN/AKT/mTOR pathway. Biomed Pharmacother. 96:229–237. 2017. View Article : Google Scholar : PubMed/NCBI
27	Ma Y, Zhang P, Gao Y, Fan H, Zhang M and Wu J: Evaluation of AKT phosphorylation and PTEN loss and their correlation with the resistance of rituximab in DLBCL. Int J Clin Exp Pathol. 8:14875–14884. 2015.PubMed/NCBI
28	Wei H, Cui R, Bahr J, Bahr J, Zanesi N, Luo Z, Meng W, Liang G and and Croce CM: miR-130a deregulates PTEN and stimulates tumor growth. Cancer Res. 77:6168–6178. 2017. View Article : Google Scholar : PubMed/NCBI
29	Yu X, Chen Y, Tian R, Li J, Li H, Lv T and Yao Q: miRNA-21 enhances chemoresistance to cisplatin in epithelial ovarian cancer by negatively regulating PTEN. Oncol Lett. 14:1807–1810. 2017. View Article : Google Scholar : PubMed/NCBI